Embryonic-like stem cells derived from postpartum placenta delivered after spotaneous labor emerging as universal prophylactic cancer vaccine

Manole Corocleanu

Private, Brasov, Romania.

DOI: 10.4236/scd.2013.34029                

Abstract

In the eighth decade of the last century extensive clinical delayed-type hypersensitivity (DTH) skin tests to an intradermal injection of a pharmaceutical allogeneic human Placenta Suspension (phPS) performed in obstetrical, gynecological and control group patients have shown positive reaction in 239 patients with clinical conditions having been as histopatrhological substratum, a hypoxia-induced adaptive/reactive epithelial cell proliferation, e.g. syncytiotrophoblastic cell hyperplasia, endometrial cell hyperplasia, or different gynecological cancers. Because the immune response against phPS has shown antigenc similarities between normal placental and endometrial hyperplastic cells and different kinds of cancer cells and because many cancers adopt an embryonic stem-like gene expression pattern, it is suggested that the profile of hypoxia-promoting placental and endometrial stem cell proliferation is more embryonic-like, and that the immune respose against phPS is expected to cross-react with tumor cells in vivo. In the process of persistent growth and accelerated oxygen consumption by hyperplastic cytotrophoblastic cells and neoplastic cells in a hypoxic microenvironment, a basic shift in energy metabolism is accompanied by appearance of heat shock proteins (HSPs), of fetal isoenzymes and of membrane glycoproteins (reappearance of oncofetal antigens, OFAs), which, as result of their overexpression/amplification may induce a host immunological response. Thus, it is assumed that phPS prepared from full-term human placentas delivered after a spontaneous labor comprises stem/progenitor cells reverted to a proliferative embryonic stem cell-like-state upon exposure to labor-inducing intrmittent placental hypoxia and that by expressing HSP/OFAs could immunize to generate immune response againjst a variety of antigens that are shared by different kinds of epithelial cancers. This immunological feature of phPS qualifies is as a vaccine-related product that may be used for a preventive cancer vaccine when mixed with a potent adjuvant (BCG-Vaccine) and given normal healthy individuals.

Keywords

Placenta; Embryonic-Like Stem Cells; Preventive Cancer Vaccine

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Corocleanu, M. (1981) Humoral and cellular reactions to placental antigens in women with pathological pregnancies and cancer patients. Revue Roumaine de Biochimie, 18, 7-13.
[2]	Corocleanu, M. (2008) A possible “universal” cancer vaccine that might cause an immune response against emerging cancer cells that originate from any tissue. Medical Hypothesis, 70, 381-383. http://dx.doi.org/10.1016/j.mehy.2007.04.040
[3]	Redman, C.W.G. (1986) Immunology of the placenta. Clinical Obstetrics and Gynecology, 16, 469.
[4]	Hamilton, M.S. (1983) Maternal immune responses to oncofetal antigens. Journal of Reproductive Immunology, 5, 249. http://dx.doi.org/10.1016/0165-0378(83)90252-8
[5]	Sarandakou, A., et al. (2007) Tumor markers in biological fluids associated with pregnancy. Critical Reviews in Clinical Laboratory Sciences, 44, 151-178. http://dx.doi.org/10.1080/104083606 01003143
[6]	Marilyn, M., et al. (2001) Human embrionic genes reexpressed in cancer cells. Oncogene, 20, 8085-8091. http://dx.doi.org/10.1038/sj.onc.1205088
[7]	Yu, J.Y., et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science, 318, 1917-1920. http://dx.doi.org/10.1126/science.1151526
[8]	Coggin Jr., J.H., Barsoum, A.L., Rohrer, J.W., Tucker, J.A. and Dyess, D.L. (2001) Materno-fetal immunobiology hypothesis: Immature laminin receptor protein is a primitive, species conserved, universal embryonic T and B cell immunogenic providing both maternal and fetal protection. Modern Aspects of Immunobiology, 2, 84-91.
[9]	Coggin Jr., J.H. and Anderson, N.G. (1974) Cancer, differentiation and embryonic antigens: Some central problems. Advances in Cancer Research, 19, 105-165. http://dx.doi.org/10.1016/S0065-230X(08)60053-6
[10]	Siegel, S., et al. (2006) Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies. The Journal of Immunology, 176, 6935-6944.
[11]	Rohrer, J.W., et al. (1999) Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes. Journal of Immunology, 162, 6880-6892.
[12]	Lee, M.W., et al. (2010) Stem and progenitor cells in human umbilical cord blood. International Journal of Hematology, 92, 45-51. http://dx.doi.org/10.1007/s12185-010-0619-4
[13]	Zhong, Z., et al. (2009) Feasibility investigation of allogeneic endometrial regenerative cells. Journal of Translational Medicine, 7, 15. http://dx.doi.org/10.1186/1479-5876-7-15
[14]	Adelman, D.M., et al. (2000) Placental cell fates are regulated in vivo by HIF-mediated hypoxia responses. Genes & Development, 14, 3191-3203.
[15]	Fryer, B.H., et al. (2006) Hypoxia, HIF and the placenta, Cell Cycle, 5, 495-498. http://dx.doi.org/ 10.4161/cc.5.5.2497
[16]	Pugh, C.W., et al. (2003) Regulation of angiogenesis by hypoxia, role of the HIF system. Nature Medicine, 9, 677-684. http://dx.doi.org/10.1038/nm0603-677
[17]	Myatt, L., et al. (2004) Oxidative stress in the placenta, Histochemistry and Cell Biology, 122, 369-382. http://dx.doi.org/10.1007/s00418-004-0677-x
[18]	Vaiman D. et al. (2005) Hypoxia-activated genes from early placenta are elevated in pre-eclampsia, but not in intra-uterine growth retardation. BMC Genomics, 6, 111. http://dx.doi.org/10.1186/1471-2164-6-111
[19]	Shigeru, S., et al. (2003) Th1/Th2 balance in preeclampsia. Journal of Reproductive Immunology, 59, 161-173. http://dx.doi.org/10.1016/S0165-0378(03)00045-7
[20]	Darmochwal-Kolarz, D., et al. (2007) Activated T lymphocytes in pre-eclampsia. American Journal of Reproductive Immunology, 58, 39-45. http://dx.doi.org/10.1111/j.1600-0897.2007.00489.x
[21]	Sasaki, Y., et al. (2007) Proportion of peripheral blood and decidual CD(4+) CD25(bright) regulatory T cells in pre-eclampsia. Clinical & Experimental Immunology, 149, 139-145. http://dx.doi.org/10.1111/ j.1365-2249.2007.03397.x
[22]	Cindrova-Davies, T., et al. (2007) Oxidative stress, gene expression, and protein changes induced in the human placenta during labor. American Journal of Pathology, 171, 1168-1179. http://dx.doi.org/ 10.2353/ajpath.2007.070528
[23]	Schmitt, E., et al. (2007) Intracellular and extracellular functions of heat shock proteins: Repercussion in cancer therapy. Journal of Leukocyte Biology, 81, 15-27. http://dx.doi.org/ 10.1189/jlb.0306167
[24]	Srivastava, P. (2002) Interaction of heat shock proteins with peptides and antigen-presenting cells: Chaperoning of the innate and adaptive immune responses. Annual Review of Immunology, 20, 395-425. http://dx.doi.org/10.1146/annurev.immunol.20.100301.064801
[25]	Yoshino, I., et al. (1994) Human tumor-infiltrating CD4+ T cells react to B cell lines expressing heat sock protein 70. The Journal of Immunology, 153, 4149-4158.
[26]	Young, L.S., et al. (1998) CD40 and epithelial cells: Across the great divide. Immunology Today, 19, 502. http://dx.doi.org/10.1016/S0167-5699(98)01340-1
[27]	Peguet-Navarro, J., et al. (1997) CD40 ligation of human keratinocytes inhibits their proliferation and induces their differentiation. The Journal of Immunology, 158, 144-152.
[28]	Contin Cécile, J., et al. (2003) Membrane-anchored CD40 is processed by the tumor necrosis factor-α-converting enzyme. Journal of Biological Chemistry, 278, 32801-32809. http://dx.doi.org/10.1074/ jbc.M209993200
[29]	Stewart, S. (2008) Alpa-fetoprotein, stem cells and cancer: How study of the production of alpha-fetoprotein during chemical hepatocarcinogenesis led to raffirmation of the stem cell theory of cancer. Tumor Biology, 29, 161-180. http://dx.doi.org/10.1159/000143402
[30]	Darrasse-Jèze, G., Bergot, A.-S., et al. (2009) Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. Journal of Clinical Investigation, 119, 2648-2662.
[31]	Goreliki, E. (1983) Concomitant immunity and the resistance to a second tumor challenge. Advances in Cancer Research, 39, 71-120. http://dx.doi.org/10.1016/S0065-230X(08)61033-7
[32]	Hock, B.D., et al. (2006) Circulating levels and clinical significance of soluble CD40 in patients with hematological malignancies. Oncology & Radiotherapy, 106, 2148-2157.
[33]	Prilliman K.R., et al. (2002) Cutting edge: A crucial role for B7-CD28 in transmitting T help from APC to CTL. The Journal of Immunology, 169, 4094-4097.
[34]	Peggs Karl, S., et al. (2009) Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. Journal of Experimental Medicine, 206, 1717-1725. http://dx.doi.org/10.1084/jem.20082492
[35]	Vasilevko, V., Ghochikyan, A., Holterman, M.J. and Agadjanyan, M.G. (2002) CD80 (B7-1) and CD86 (B7-2) are functionally equivalent in the initiation and maintenance of CD4+ T-cell proliferation after activation with suboptimal doses of PHA. DNA and Cell Biology, 21, 137-149. http://dx.doi.org/ 10.1089/10445490252925404
[36]	Becker, Th., et al. (2002) CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. The Journal of Cell Biology, 158, 1277-1285. http://dx.doi.org/10.1083/jcb.200208083
[37]	Finn, O.J., et al. (2002) Prophylactic cancer vaccines. Current Opinion in Immunology, 14, 172-177. http://dx.doi.org/10.1016/S0952-7915(02)00317-5